lisa_labSD said:

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

This is my experience too, for whatever a second data point is worth.

PharmacoVig_BOS said:

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

PharmacoVig_BOS said:

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 11 months of treatment.

The 5 criteria (and my journey):

1. Waist circumference: 50" → 34" ✅ Resolved
2. Triglycerides: 228 → 108 ✅ Resolved
3. HDL: 34 → 60 ✅ Resolved
4. Blood pressure: 148/94 → 121/75 ✅ Resolved
5. Fasting glucose: 123 → 86 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

One thing that is still open after PharmacoVig_BOS’s answer:

Did your prescriber agree with that reading, and if not what was their objection?

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Report rather than reply if it drifts again.